Abstract
Trastuzumab (TRA) is a commonly used anti-HER2 directed agent among breast cancer (BC) patients in the adjuvant and metastatic settings, however, real-world evidence of retreatment with TRA in the metastatic setting is lacking. We describe TRA use among HER2-positive (HER2+) metastatic breast cancer (MBC) patients in an electronic health records database.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
